緑内障市場規模、シェア、成長分析、タイプ別、薬剤クラス別、投与法別、最終用途別、流通別、地域別 - 産業別予測、2024～2031年

緑内障の世界市場規模は2022年に81億米ドルと評価され、2023年の86億3,000万米ドルから2031年には144億米ドルに成長し、予測期間（2024～2031年）のCAGRは6.6%で成長する見通しです。

世界の緑内障市場は一貫した成長を遂げており、特に高齢化社会と慢性的な眼疾患を持つ人々の間で、この慢性的な眼疾患の有病率が上昇していることが主な要因となっています。低侵襲手術やレーザー治療などの診断・治療技術の進歩が、市場の拡大をさらに後押ししています。しかし、治療費の高騰や地域によっては医療アクセスが限られているなどの課題が、成長の障害となっています。競合情勢は、主要業界プレイヤーの活発な活動によって特徴付けられ、革新的な情勢管理ソリューションの継続的な研究開発を後押ししています。緑内障に対する認識、早期発見、治療オプションの改善が進むにつれ、世界の緑内障市場は今後数年間で安定的に成長すると予想され、この重大な健康問題への取り組みの重要性が強調されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

緑内障市場規模：タイプ別およびCAGR（2024～2031年）

• 市場概要
• 閉塞隅角緑内障（CAG）
• 開放隅角緑内障（OAG）
• 続発緑内障
• 先天性緑内障
• その他

緑内障市場規模：薬剤クラス別およびCAGR（2024～2031年）

• 市場概要
• ベータ遮断薬
• プロスタグランジン
• アルファアドレナリン作動薬
• 炭酸脱水酵素阻害剤
• 併用薬
• その他

緑内障市場規模：投与法別およびCAGR（2024～2031年）

• 市場概要
• 経口
• 注射
• 硝子体内
• その他

緑内障市場規模：最終用途別およびCAGR（2024～2031年）

• 市場概要
• 病院
• 専門センター
• その他

緑内障市場規模：流通別およびCAGR（2024～2031年）

• 市場概要
• 病院
• オンライン
• 小売り

緑内障市場規模およびCAGR（2024～2031年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021～2023年）

主要企業プロファイル

• Aerie Pharmaceuticals（USA）
• Akorn, Inc.（USA）
• AbbVie Inc.（USA）
• Bausch Health Companies Inc.（Canada）
• Inotek Pharmaceuticals Corp.（USA）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Glaukos Corporation（USA）
• Ocular Therapeutix, Inc.（USA）
• Santen Inc.（Japan）
• Ono Pharmaceutical Co., Ltd.（Japan）
• Nicox S.A.（France）
• Sun Pharmaceutical Industries Ltd.（India）
• Visiox Pharma（USA）
• TearClear（USA）
• MediPrint Ophthalmics（formerly Leo Lens Pharma）（Denmark）
• Tarsier Pharma（USA）
• Peregrine Ophthalmic（USA）

結論と推奨事項

Global Glaucoma Market size was valued at USD 8.1 billion in 2022 and is poised to grow from USD 8.63 billion in 2023 to USD 14.4 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).

The global glaucoma market is experiencing consistent growth, primarily fueled by the rising prevalence of this chronic eye condition, particularly among the aging population and those with chronic eye diseases. Advancements in diagnostic and treatment technologies, including minimally invasive surgeries and laser therapies, further bolster market expansion. However, challenges such as high treatment costs and limited healthcare access in certain areas pose obstacles to growth. The competitive landscape is marked by significant activity among key industry players, driving continuous research and development for innovative glaucoma management solutions. As awareness, early detection, and improved treatment options progress, the global glaucoma market is anticipated to grow steadily in the coming years, underscoring the importance of addressing this critical health issue.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glaucoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glaucoma Market Segmental Analysis

Global Glaucoma Market is segmented by type, drug class, administration, end use, distribution and region. Based on type, the market is segmented into closed angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and others. Based on drug class, the market is segmented into beta blockers, prostaglandins, alpha adrenergic agonist, carbonic anhydrase inhibitors, combination drugs and others. Based on administration, the market is segmented into oral, injections, intravitreal and other. Based on end use, the market is segmented into hospitals, specialty centers and others. Based on distribution, the market is segmented into hospital, online and retail. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glaucoma Market

A significant impetus for the global glaucoma market stems from the escalating prevalence of the condition across the globe. This surge is primarily driven by an aging population and a rise in chronic illnesses, including diabetes and hypertension, which heighten the likelihood of glaucoma development. Given that glaucoma is a major contributor to irreversible blindness, there is an urgent requirement for early detection, diagnosis, and treatment options. Consequently, this situation stimulates demand for cutting-edge glaucoma management solutions, encompassing advanced diagnostic equipment, effective medications, and surgical treatments, all aimed at improving patient outcomes and reducing the risk of vision loss.

Restraints in the Global Glaucoma Market

The global glaucoma market faces significant restraints primarily due to limited awareness and inadequate routine screening practices for this condition in various regions. As glaucoma often presents asymptomatically in its early stages, the absence of regular eye exams complicates timely diagnosis. This lack of awareness among both the general public and healthcare providers can result in late-stage diagnosis and subsequent irreversible vision loss. Additionally, the high costs associated with managing glaucoma-encompassing medications, surgical interventions, and long-term care-pose substantial barriers to access, particularly for patients in low- and middle-income countries, further exacerbating the challenges in glaucoma management and treatment.

Market Trends of the Global Glaucoma Market

The global glaucoma market is witnessing a significant trend towards the adoption of advanced diagnostic technologies and innovative treatment modalities, driven by the urgent need for early detection and management of this potentially debilitating eye disease. As awareness increases regarding the irreversible vision loss associated with glaucoma, healthcare providers are prioritizing regular screenings and advanced imaging techniques for timely diagnosis. Technologies like optical coherence tomography (OCT), visual field testing, and advanced tonometry are increasingly utilized to enhance diagnostic accuracy and patient monitoring. This trend is fostering a robust market environment, as both established and emerging players invest in cutting-edge solutions to better address patient needs and optimize treatment outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Glaucoma Market Size by Type & CAGR (2024-2031)

• Market Overview
• Closed Angle Glaucoma (CAG)
• Open Angle Glaucoma (OAG)
• Secondary Glaucoma
• Congenital Glaucoma
• Others

Global Glaucoma Market Size by Drug Class & CAGR (2024-2031)

• Market Overview
• Beta Blockers
• Prostaglandins
• Alpha Adrenergic Agonist
• Carbonic Anhydrase Inhibitors
• Combination Drugs
• Others

Global Glaucoma Market Size by Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Injections
• Intravitreal
• Other

Global Glaucoma Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Specialty Centers
• Others

Global Glaucoma Market Size by Distribution & CAGR (2024-2031)

• Market Overview
• Hospital
• Online
• Retail

Global Glaucoma Market Size & CAGR (2024-2031)

• North America (Type, Drug Class, Administration, End Use, Distribution)
  • US
  • Canada
• Europe (Type, Drug Class, Administration, End Use, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Administration, End Use, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Administration, End Use, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Administration, End Use, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Aerie Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotek Pharmaceuticals Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glaukos Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nicox S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Visiox Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TearClear (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediPrint Ophthalmics (formerly Leo Lens Pharma) (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsier Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Peregrine Ophthalmic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations